Arvinas, Inc. (NASDAQ:ARVN) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Arvinas, Inc. (NASDAQ:ARVN) has been given a consensus recommendation of “Moderate Buy” by the sixteen brokerages that are currently covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and fourteen have issued a buy recommendation on the company. The average 1-year price target among brokers that have covered the stock in the last year is $59.73.

ARVN has been the subject of several recent research reports. Leerink Partnrs reaffirmed an “outperform” rating on shares of Arvinas in a report on Thursday, February 22nd. Wedbush upped their target price on shares of Arvinas from $33.00 to $59.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 28th. HC Wainwright lowered their target price on Arvinas from $90.00 to $87.00 and set a “buy” rating on the stock in a report on Friday, April 12th. Citigroup downgraded shares of Arvinas from a “buy” rating to a “neutral” rating and upped their price target for the company from $36.00 to $55.00 in a report on Wednesday, February 14th. Finally, Barclays boosted their target price on shares of Arvinas from $26.00 to $60.00 and gave the company an “overweight” rating in a research note on Thursday, February 29th.

Arvinas Stock Performance

Arvinas stock opened at $32.37 on Friday. Arvinas has a fifty-two week low of $13.57 and a fifty-two week high of $53.08. The stock has a 50-day simple moving average of $41.53 and a 200-day simple moving average of $34.55. The company has a market capitalization of $2.21 billion, a P/E ratio of -4.98 and a beta of 1.94.

Arvinas (NASDAQ:ARVN) last posted its quarterly earnings data on Tuesday, February 27th. The company reported ($2.53) EPS for the quarter, missing analysts’ consensus estimates of ($1.15) by ($1.38). The business had revenue of ($43.10) million during the quarter, compared to analyst estimates of $38.91 million. Arvinas had a negative net margin of 185.09% and a negative return on equity of 70.24%. During the same quarter in the prior year, the firm posted ($1.56) earnings per share. As a group, analysts forecast that Arvinas will post -5.02 earnings per share for the current year.

Insider Transactions at Arvinas

In related news, CEO John G. Houston sold 5,196 shares of the company’s stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $47.05, for a total transaction of $244,471.80. Following the completion of the sale, the chief executive officer now directly owns 1,036,681 shares of the company’s stock, valued at approximately $48,775,841.05. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, CEO John G. Houston sold 5,196 shares of the business’s stock in a transaction that occurred on Friday, February 23rd. The stock was sold at an average price of $47.05, for a total transaction of $244,471.80. Following the transaction, the chief executive officer now directly owns 1,036,681 shares of the company’s stock, valued at approximately $48,775,841.05. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Ronald Peck sold 1,699 shares of the company’s stock in a transaction that occurred on Friday, February 23rd. The stock was sold at an average price of $47.05, for a total value of $79,937.95. Following the completion of the transaction, the insider now owns 67,516 shares of the company’s stock, valued at approximately $3,176,627.80. The disclosure for this sale can be found here. Insiders sold 8,597 shares of company stock valued at $404,489 over the last 90 days. Corporate insiders own 5.23% of the company’s stock.

Hedge Funds Weigh In On Arvinas

A number of institutional investors have recently added to or reduced their stakes in ARVN. RTW Investments LP acquired a new stake in shares of Arvinas during the fourth quarter valued at about $173,427,000. Price T Rowe Associates Inc. MD grew its stake in Arvinas by 42.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 3,832,123 shares of the company’s stock valued at $157,731,000 after purchasing an additional 1,143,452 shares in the last quarter. Commodore Capital LP acquired a new stake in Arvinas during the 4th quarter valued at approximately $41,160,000. Norges Bank purchased a new stake in Arvinas during the 4th quarter worth approximately $36,126,000. Finally, Boxer Capital LLC acquired a new position in shares of Arvinas in the 4th quarter valued at approximately $25,051,000. Institutional investors and hedge funds own 95.19% of the company’s stock.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.